Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary

Journal of B.U.ON.

Volumn 14, Issue 4, 2009, Pages 635-639

  Karaferic, Andjela ^a   Jovanovic, D ^a   Jelic, S ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

CA 19 9; CA 125; Classic mucinous ovarian cancer; Estrogen progesterone receptors; HER2 neu; Serous papillary ovarian cancer

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER TISSUE; CELL MEMBRANE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MUCINOUS CARCINOMA; OVARY CARCINOMA; PAPILLARY CARCINOMA; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

ADENOCARCINOMA, MUCINOUS; CA-125 ANTIGEN; CA-19-9 ANTIGEN; CELL MEMBRANE; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 75149129159     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Petković S (Ed). Gynecology. Beograd: Elit-Medica, 2004.
2. Scully RE. Ovarian tumors. A review. Am J Pathol 1997; 87: 686-720.
3. Kurman RJ (Ed). Blaustein's Pathology of the Female Genital Tract (5th Edn). New York: Springer-Verlag, 2002.
4. Fox H (Ed). Haines and Taylor Obstetrical and Gynecological Pathology (5th Edn). New York: Churchill Livingstone, 2003, pp 693-820.
5. Robboy SJ, Andreson MC, Russell P (Eds). Pathology of Female Reproductive Tract. London: New York: Churchill Livingstone, 2002, pp 539-691.
6. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351; 2519-2529.
7. McCluggage WG. Recent advances in immunohistochemistry in the diagnosis of ovarian neoplasms. J Clin Pathol 2000; 53:327-334.
8. Deavers MT, Malpica A, Silva EG. Immunohistochemistry in gynecological pathology. J Gynecol Cancer 2003; 13: 567-579.
9. Bratthuer GL, Adams LR. Immunohistochemistry: antigen detection in tissue. In: Mikel UV (Ed): Advanced Laboratory Methods in Histology and Pathology. Washington, DC: Armed Forces Institute of Pathology, 1994, pp 1-40.
10. David J, Dabbs MD (Eds). Diagnostic immunohistochemistry. New York, Edinburgh, London, Philadelphia: Churchill Livingstone, 2002.
11. Shuk-Mei H. Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol 2003; 1:73-80.
12. McIntire R. Tumor markers. In: De Vita V, Hellman S, Rosenberg S (Eds): Cancer: Principles & Practice of Oncology (4th Edn). Philadelphia: Lippincott Co, 1989, pp 375-388.
13. Schutter E, Davelaar E, Van Kamp G, Vertstraeten R, Kenemans P, Verhejen R. The differential diagnostic potential of panel of tumor markers (CA 125, CA 19-9 CA 15-3) in patients with pelvic mass. Am J Obstet Gynecol 2002; 187:385-392.
14. Rubin E, Gorstein F, Rubin R, Schwartin R, Strayer D (Eds). Rubin's Pathology (4th Edn). Philadelphia: Lippincott Williams & Wilkins, 2004.
15. Bast RC, Knapp RC. Human markers for epithelial ovarian carcinoma. In: River S (Ed): Ovarian malignancies: Diagnostic and Therapeutic advances. Edinburgh - New York. Churchill Livingstone, 1987, pp 11-25.
16. Konich I, Fujii S, Okamura H et al. Analysis of serum CA 125, CEA, AFP, LDH, and CA 19-9 in patients with ovarian tumors - correlation between tumor markers and histological types of ovarian tumors. Nippon Sanka Fujinka Gakkai Zasshi 1986; 38:827-836.
17. Berchuck A, Olt GJ, Soisson AP. Heterogeneity of antigen expression in advanced epithelial ovarian cancer. Am J Obstet Gynecol 1990; 162:883-888.
18. Zurawski VR, Davis HM, Finkler NJ. Tissue distribution and characteristics of the CA 125 antigen. Cancer Rev 1988; 11-12:102-118.
19. Finkler NJ, Muto MG, Kassis AI. Intraperitoneal radiolabeled OC 125 in patients with advanced epithelial ovarian cancer. Gynecol Oncol 1989; 34:339-344.
20. Berchuck A, Kamel A, Whitaker R. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990; 50:4087-4091.
21. Peter R, Lingren SC. Estrogen and progesterone receptors in ovarian epithelial tumors. Mol Cell Endocrinol 2004; 221: 97-104.
22. Coughlin SS, Giustozzia A, Smith SJ et al. A meta analysis of estrogen replacement therapy and risk of epithelial cancer. J Clin Epidemiol 2000; 53:367-375.
23. Rimman T, Dickman PW, Nilsson S et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002; 94:497-504.
24. Lee P, Rosen DG, Zhu C et al. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol 2005: 96:671-677.